Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin versus placebo in progressive multiple sclerosis
2009-011516-37Phase 2Completed
- Sponsor
- Danish Multiple Sclerosis Research Centre
- Start
- May 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing NeoRecormon with Placebo (2 arms). Primary endpoint: Change in composite disability score at 24 weeks. Started May 2009; status: completed.
02
Drugs
epoetin beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-011516-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011516-37.